Status:

Red

Decision Date:

November 2021

Comments

RED: National Orbis Drug Access Arrangements – sotorasib as monotherapy for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) exhibiting a KRAS G12C mutation and who have been previously treated with at least 1 prior systemic therapy for advanced NSCLC

RED: NICE TA781 - Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (Decision date - April 2022)

Red Drug Classifications

• 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
• 5: Is new to clinical practice and unfamiliar, necessitating a period of accumulation of experience, firstly (and most rapidly) by consultants/specialists

search again